Cinacalcet HCl Prevents Development of Parathyroid Gland Hyperplasia and Reverses Established Parathyroid Gland Hyperplasia in a Rodent Model of CKD

Overview

Journal Nephrol Dial Transplant

Publisher Oxford University Press

Specialties General Surgery
Nephrology

Date 2011 Nov 1

PMID 22036941

Citations 16

Authors

Gerald Miller

James Davis

Edward Shatzen

Matthew Colloton

David Martin

Charles M Henley

Affiliations

Soon will be listed here.

Abstract

Background: Secondary hyperparathyroidism (sHPT) represents an adaptive response to progressively impaired control of calcium, phosphorus and vitamin D in chronic kidney disease (CKD). It is characterized by parathyroid hyperplasia and excessive synthesis and secretion of parathyroid hormone (PTH). Parathyroid hyperplasia in uremic rats can be prevented by calcium-sensing receptor (CaSR) activation with the calcimimetic cinacalcet (Sensipar®/Mimpara®); however, it is unknown, how long the effects of cinacalcet persist after withdrawal of treatment or if cinacalcet is efficacious in uremic rats with established sHPT.

Methods: We sought to determine the effect of cinacalcet discontinuation in uremic rats and whether cinacalcet was capable of influencing parathyroid hyperplasia in animals with established sHPT.

Results: Discontinuation of cinacalcet resulted in reversal of the beneficial effects on serum PTH and parathyroid hyperplasia. In rats with established sHPT, cinacalcet decreased serum PTH and mediated regression of parathyroid hyperplasia. The cinacalcet-mediated decrease in parathyroid gland size was accompanied by increased expression of the cyclin-dependent kinase inhibitor p21. Prevention of cellular proliferation with cinacalcet occurred despite increased serum phosphorus and decreased serum calcium.

Conclusions: The animal data provided suggest established parathyroid hyperplasia can be reversed by modulating CaSR activity with cinacalcet and that continued treatment may be necessary to maintain reductions in PTH.

Citing Articles

The calcium-sensing receptor in inflammation: Recent updates.

Iamartino L, Brandi M Front Physiol. 2022; 13:1059369.

PMID: 36467702 PMC: 9716066. DOI: 10.3389/fphys.2022.1059369.

Mechanism of calcitriol regulating parathyroid cells in secondary hyperparathyroidism.

Xiang Z, Wang M, Miao C, Jin D, Wang H Front Pharmacol. 2022; 13:1020858.

PMID: 36267284 PMC: 9577402. DOI: 10.3389/fphar.2022.1020858.

Cinacalcet and primary hyperparathyroidism: systematic review and meta regression.

Ng C, Chin Y, Tan M, Ng J, Yang S, Kiew J Endocr Connect. 2020; 9(7):724-735.

PMID: 32621588 PMC: 7424342. DOI: 10.1530/EC-20-0221.

Evocalcet prevents ectopic calcification and parathyroid hyperplasia in rats with secondary hyperparathyroidism.

Sakai M, Tokunaga S, Kawai M, Murai M, Kobayashi M, Kitayama T PLoS One. 2020; 15(4):e0232428.

PMID: 32343734 PMC: 7188245. DOI: 10.1371/journal.pone.0232428.

Recurrent Metastasized Parathyroid Carcinoma-Long-Term Remission After Combined Treatments With Surgery, Radiotherapy, Cinacalcet, Zoledronic Acid, and Temozolomide.

Storvall S, Ryhanen E, Bensch F, Heiskanen I, Kytola S, Ebeling T JBMR Plus. 2019; 3(4):e10114.

PMID: 31044184 PMC: 6478586. DOI: 10.1002/jbm4.10114.

References

Niculescu 3rd A, Chen X, Smeets M, Hengst L, Prives C, Reed S . Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol. 1998; 18(1):629-43. PMC: 121530. DOI: 10.1128/MCB.18.1.629. View

Galitzer H, Ben-Dov I, Silver J, Naveh-Many T . Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int. 2009; 77(3):211-8. DOI: 10.1038/ki.2009.464. View

Kifor O, Moore Jr F, Wang P, Goldstein M, Vassilev P, KIFOR I . Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab. 1996; 81(4):1598-606. DOI: 10.1210/jcem.81.4.8636374. View

Chin J, Miller S, Wada M, Nagano N, Nemeth E, Fox J . Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats. J Am Soc Nephrol. 2000; 11(5):903-911. DOI: 10.1681/ASN.V115903. View

Colloton M, Shatzen E, Miller G, Stehman-Breen C, Wada M, Lacey D . Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int. 2005; 67(2):467-76. DOI: 10.1111/j.1523-1755.2005.67103.x. View

Rodriguez M, Nemeth E, Martin D . The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism. Am J Physiol Renal Physiol. 2004; 288(2):F253-64. DOI: 10.1152/ajprenal.00302.2004. View

Tokumoto M, Tsuruya K, Fukuda K, Kanai H, Kuroki S, Hirakata H . Reduced p21, p27 and vitamin D receptor in the nodular hyperplasia in patients with advanced secondary hyperparathyroidism. Kidney Int. 2002; 62(4):1196-207. DOI: 10.1111/j.1523-1755.2002.kid585.x. View

Canalejo A, Canalejo R, Rodriguez M, Martinez-Moreno J, Felsenfeld A, Rodriguez M . Development of parathyroid gland hyperplasia without uremia: role of dietary calcium and phosphate. Nephrol Dial Transplant. 2009; 25(4):1087-97. DOI: 10.1093/ndt/gfp616. View

Yano S, Sugimoto T, Tsukamoto T, Chihara K, Kobayashi A, Kitazawa S . Association of decreased calcium-sensing receptor expression with proliferation of parathyroid cells in secondary hyperparathyroidism. Kidney Int. 2000; 58(5):1980-6. DOI: 10.1111/j.1523-1755.2000.00370.x. View

10.

Henley C, Davis J, Miller G, Shatzen E, Cattley R, Li X . The calcimimetic AMG 641 abrogates parathyroid hyperplasia, bone and vascular calcification abnormalities in uremic rats. Eur J Pharmacol. 2009; 616(1-3):306-13. PMC: 6854701. DOI: 10.1016/j.ejphar.2009.05.013. View

11.

Cunningham J, Locatelli F, Rodriguez M . Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol. 2011; 6(4):913-21. DOI: 10.2215/CJN.06040710. View

12.

Li Y, Amling M, Pirro A, Priemel M, Meuse J, Baron R . Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice. Endocrinology. 1998; 139(10):4391-6. DOI: 10.1210/endo.139.10.6262. View

13.

Gogusev J, Duchambon P, Hory B, Giovannini M, Goureau Y, Sarfati E . Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int. 1997; 51(1):328-36. DOI: 10.1038/ki.1997.41. View

14.

Komaba H, Fukagawa M . Regression of parathyroid hyperplasia by calcimimetics--fact or illusion?. Nephrol Dial Transplant. 2008; 24(3):707-9. DOI: 10.1093/ndt/gfn717. View

15.

Charytan C, Coburn J, Chonchol M, Herman J, Lien Y, Liu W . Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am J Kidney Dis. 2005; 46(1):58-67. DOI: 10.1053/j.ajkd.2005.04.013. View

16.

Sherr C, Roberts J . Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 1995; 9(10):1149-63. DOI: 10.1101/gad.9.10.1149. View

17.

Ben-Dov I, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-O M, Mohammadi M . The parathyroid is a target organ for FGF23 in rats. J Clin Invest. 2007; 117(12):4003-8. PMC: 2066196. DOI: 10.1172/JCI32409. View

18.

Ho C, Conner D, Pollak M, Ladd D, Kifor O, WARREN H . A mouse model of human familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Nat Genet. 1995; 11(4):389-94. DOI: 10.1038/ng1295-389. View

19.

Dusso A, Pavlopoulos T, Naumovich L, Lu Y, Finch J, Brown A . p21(WAF1) and transforming growth factor-alpha mediate dietary phosphate regulation of parathyroid cell growth. Kidney Int. 2001; 59(3):855-65. DOI: 10.1046/j.1523-1755.2001.059003855.x. View

20.

Brown A, Ritter C, Finch J, Slatopolsky E . Decreased calcium-sensing receptor expression in hyperplastic parathyroid glands of uremic rats: role of dietary phosphate. Kidney Int. 1999; 55(4):1284-92. DOI: 10.1046/j.1523-1755.1999.00386.x. View